Tag: GILD

FB Nasdaq FB Facebook
Finance

Investor’s Watch List: Gilead Sciences (NASDAQ:GILD), Consolidated Communications Holdings (NASDAQ:CNSL), GT Advanced Technologies Inc (NASDAQ:GTAT), Novartis (NYSE:NVS)

Gilead Sciences, Inc. (NASDAQ:GILD) company on Mar. 28 announced that it has elected to settle its conversion obligations in connection with any 1.00% Senior Convertible Notes due 2014 (the “Notes”) submitted for conversion on or after February 1, 2014 entirely in cash. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was 3.92% in last session and finished the day at $73.64. Traded volume was 19,465,500 million shares … Continue reading Investor’s Watch List: Gilead Sciences (NASDAQ:GILD), Consolidated Communications Holdings (NASDAQ:CNSL), GT Advanced Technologies Inc (NASDAQ:GTAT), Novartis (NYSE:NVS)

Colin Pettis
FB Nasdaq FB Facebook
Diversified Tech

Healthcare Active Stocks: Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Bristol-Myers Squib (NYSE:BMY), Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

Congress jumped into the health care game (again) by “complaining” that Gilead Sciences, Inc. (NASDAQ:GILD)’s hepatitis drug was priced too high. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was 3.92% in last session and finished the day at $73.64. Traded volume was 19.50million shares in the last session and the average volume of the stock remained 13.29million shares. The beta of the stock remained 0.55. Gilead … Continue reading Healthcare Active Stocks: Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Bristol-Myers Squib (NYSE:BMY), Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

Jason Knox
Finance

Biotech Most Active Stocks: Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Arena Pharmaceuticals (NASDAQ:ARNA), MannKind Corporation (NASDAQ:MNKD)

Gilead Sciences, Inc. (NASDAQ:GILD) was active yesterday as one Bloomberg reporter thinks he has another take on the recent Waxman letter. Drew Armstrong — via his own Twitter account — said Gilead execs had a meeting scheduled with Waxman all along and the letter just seemed like Waxman was making an effort to drag them in. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was 3.37% in … Continue reading Biotech Most Active Stocks: Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Arena Pharmaceuticals (NASDAQ:ARNA), MannKind Corporation (NASDAQ:MNKD)

Mark DeFrance
Finance

Biotech Most Active Stocks: Gilead Sciences (NASDAQ:GILD), EXACT Sciences Corporation (NASDAQ:EXAS), Endocyte (NASDAQ:ECYT), Arena Pharmaceuticals (NASDAQ:ARNA)

Gilead Sciences Inc. (NASDAQ:GILD) announced that it has elected to settle its conversion obligations in connection with any 1.00% Senior Convertible Notes due 2014 (the “Notes”) submitted for conversion on or after February 1 2014 entirely in cash. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was -4.01% in last session and finished the day at $68.55. Traded volume was 29.25million shares in the last session and … Continue reading Biotech Most Active Stocks: Gilead Sciences (NASDAQ:GILD), EXACT Sciences Corporation (NASDAQ:EXAS), Endocyte (NASDAQ:ECYT), Arena Pharmaceuticals (NASDAQ:ARNA)

Kevin Long
Finance

Healthcare Active Runners: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Inovio Pharmaceuticals (NYSEMKT:INO), Johnson & Johnson (NYSE:JNJ)

Pfizer Inc. (NYSE:PFE) announced encouraging top-line data from a phase IIIb study evaluating Genotropin for increasing height in small-for-gestational-age (SGA) children aged between 24 and 30 months. Pfizer Inc. (NYSE:PFE) stock performance was -0.25% in last session and finished the day at $32.10. Traded volume was 27.74million shares in the last session and the average volume of the stock remained 26.63million shares. The beta of … Continue reading Healthcare Active Runners: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Inovio Pharmaceuticals (NYSEMKT:INO), Johnson & Johnson (NYSE:JNJ)

Jayne Crisman
Finance

Healthcare Most Active: Pfizer Inc. (NYSE:PFE), Bristol-Myers Squibb (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), MannKind Corporation (NASDAQ:MNKD)

Pfizer Inc. (NYSE:PFE) announced that PROFILE 1014, a phase 3 study of anaplastic lymphoma kinase (ALK) inhibitor Xalkori (crizotinib), met its primary objective of significantly prolonging progression-free survival (PFS) in previously untreated patients with ALK-positive advanced non-squamous non-small cell lung cancer (NSCLC) when compared to standard platinum-based chemotherapy regimens. Pfizer Inc. (NYSE:PFE) stock performance was 1.13% in last session and finished the day at $32.18. … Continue reading Healthcare Most Active: Pfizer Inc. (NYSE:PFE), Bristol-Myers Squibb (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), MannKind Corporation (NASDAQ:MNKD)

Colin Pettis